Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer
| 対象疾患 | Invasive Breast Cancer |
|---|---|
| 相 | 第2相 |
| スポンサー | Medical College of Wisconsin |
| ステータス | 実施中（募集終了） |
| 参加者数 | 36 名 |
| 介入（薬剤） | Cemiplimab, Paclitaxel, Carboplatin (not mandatory), Doxorubicin, Cyclophosphamide |
| 開始日 | 2020年3月5日 |
| 完了日 | 2025年8月11日 |
| 結果公開日 | 2026年7月27日 |
概要
This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis of invasive breast cancer, clinical stage tumor 1-3 (cT1-T3), node 0-3 (cN0-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PR+) human epidermal growth factor receptor 2 (HER2) negative or hormone receptor-negative (HR-) (estrogen-receptor-negative (ER-) and progesterone-receptor-negative (PR-) human epidermal growth factor receptor 2 (HER2) negative/triple-negative breast cancer.
The Proportion of Breast Cancer Patients With Pathological Complete Response (pCR).
| Drug Treatment | 24.2 percentage of subjects |
|---|---|
| Drug Treatment | 75.8 percentage of subjects |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Vitamin D and Physical Activity on Bone Health — University of Rochester
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in T — National Cancer Institute (NCI)
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor — National Cancer Institute (NCI)
- Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced — National Cancer Institute (NCI)
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Can — AstraZeneca
- Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Adm — University of Colorado, Denver